Glaxosmithkline Pharmaceuticals Ltd Financials
Company Logo

Glaxosmithkline Pharmaceuticals Ltd Financial Statement

Glaxosmithkline Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2025
Revenue848.59
Operating Expense554.08
Net Profit204.70
Net Profit Margin24.12
Earning Per Share12.08
EBIDTA294.49
Effective Tax Rate25.08

Glaxosmithkline Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual3,723.49
Operating Expenses Annual2,554.20
Operating Profit Annual1,316.54
Interest Annual1.31
Depreciation56.57
Net Profit Annual919.05
Tax Annual329.39

Glaxosmithkline Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning62.15
Cash Flow from Operations1,280.03
Cash Flow from Investing-36.53
Cash Flow from Financing-769.42
Cash Flow at the End536.22

Glaxosmithkline Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)35.36
PBIT Margin (%)33.56
PBT Margin (%)7.94
Net PROFIT Margin (%)24.68
Return On Networth / Equity (%)49.23
Return On Networth /Employed (%)58.72
Return On Assets (%)43.19
Total Debt / Equity (X)0.01
Asset Turnover Ratio (%)1.75

Glaxosmithkline Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual282.87
Total Current Assets Annual3,383.55
Non Current Assets Annual717.38
Total Shareholders Funds Annual1,949.23
Total Assets Annual4,100.93

Glaxosmithkline Pharmaceuticals Ltd Earning Calls

EPS (INR)

Expected

12.10

Reported

12.10

Surprise

0.00%

Mar 2025

EPS beaten by 0.00%

Dec 2024

EPS beaten by 0.00%

Sep 2024

EPS beaten by 0.00%

FAQS on Glaxosmithkline Pharmaceuticals Ltd Financials

As of Aug 16, 2025, Glaxosmithkline Pharmaceuticals Ltd has a market capitalization of 48,743.20 Cr. Value Research classifies it as a Large-Cap company.

Yes, Glaxosmithkline Pharmaceuticals Ltd is with a debt-to-equity ratio of 0.01.

In FY 2024 , Glaxosmithkline Pharmaceuticals Ltd recorded a total revenue of approximately 3,723.49 Cr marking a significant milestone in the company's financial performance.

Glaxosmithkline Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.4% and 0.1% annually, respectively..

Glaxosmithkline Pharmaceuticals Ltd's current PE ratio is 53.04.

Glaxosmithkline Pharmaceuticals Ltd's ROCE averaged 54.7% from the FY ending March 2023 to 2025, with a median of 52.9%. It peaked at 63.8% in March 2025, reflecting strong capital efficiency over the period..

Glaxosmithkline Pharmaceuticals Ltd's latest EBIT is Rs. 1,249.75 Cr, surpassing the average EBIT of Rs. 965.94 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions